Expert on Studies of the PSA Test in Prostate Cancer

Video

In Partnership With:

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center discusses studies of the controversial prostate-specific antigen (PSA) test for patients with prostate cancer.

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center discusses studies of the controversial prostate-specific antigen (PSA) test for patients with prostate cancer.

Going back to Swedish data, it has been determined that a midlife PSA test is strongly predictive of long-term risk of aggressive prostate cancer, but a PSA test is not a beneficial test for prostate cancer, explains Vickers.

Studies have also tried to determine how much getting a PSA test advances the time of when a patient has cancer compared to when they show up to the clinic and are diagnosed.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD